Cargando…
Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer
BACKGROUND: Programmed death ligand‐1 (PD‐L1) expression predicts immunotherapy utility in nononcogenic addictive lung adenocarcinoma (ADC). However, its reproducibility and reliability may be compromised outside clinical trials. This study aimed to evaluate factors associated with PD‐L1 expression...
Autores principales: | Avilés‐Salas, Alejandro, Flores‐Estrada, Diana, Lara‐Mejía, Luis, Catalán, Rodrigo, Cruz‐Rico, Graciela, Orozco‐Morales, Mario, Heredia, David, Bolaño‐Guerra, Laura, Soberanis‐Piña, Pamela Denisse, Varela‐Santoyo, Edgar, Cardona, Andrés F., Arrieta, Oscar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715877/ https://www.ncbi.nlm.nih.gov/pubmed/36317227 http://dx.doi.org/10.1111/1759-7714.14695 |
Ejemplares similares
-
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells
por: Cruz-Rico, Graciela, et al.
Publicado: (2021) -
Myoepithelial Carcinoma Arising in a Plasmacytoid Myoepithelioma of the Parotid Gland Synchronized with Melanoma: A Case Report and Review of the Literature
por: Soberanis-Piña, Pamela Denisse, et al.
Publicado: (2021) -
Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
por: Orozco-Morales, Mario, et al.
Publicado: (2021) -
LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer
por: Avilés-Salas, Alejandro, et al.
Publicado: (2022) -
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)